Litigation Details for Indivior Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2018)

Indivior Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2018)

Docket		Date Filed	2018-04-04
Court	District Court, D. Delaware	Date Terminated	2019-09-16
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	9,687,454; 9,855,221; 9,931,305
Link to Docket	External link to docket

Details for Indivior Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-04-04				External link to document
2018-04-04	63	Amended Answer to Complaint	207387 to the FDA infringed claims of U.S. Patent No. 9,855,221. See, e.g., C.A. No. 18-497-RGA, D.I. 6.…the ’454 patent as the assignee. Defendant further admits that, on its face, the ’454 patent is titled… copy of the ’454 patent. Defendant avers that the allegation that the ’454 patent was duly and legally…are required to disclose to the FDA the patent numbers of patents claiming the drug or method of using … THE PATENT-IN-SUIT 12. The ’454 patent, entitled “Sublingual and Buccal	External link to document
2018-04-04	73	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,687,454 B2. (nms) (Entered… 16 September 2019 1:18-cv-00499 830 Patent None District Court, D. Delaware	External link to document

Indivior Inc. v. Actavis Laboratories UT, Inc. Litigation Summary and Patent Analysis, 1:18-cv-00499

Last updated: September 8, 2026

Indivior Inc. sued Actavis Laboratories UT, Inc. in the U.S. District Court for the District of Delaware after Actavis filed an abbreviated new drug application seeking approval for a generic version of Suboxone sublingual film, a buprenorphine/naloxone product. Indivior asserted patents covering the film dosage form and its drug-delivery composition, including U.S. Patent Nos. 8,603,514 and 9,931,305. The case was an ANDA patent action under the Hatch-Waxman Act.

The litigation did not produce a reported merits judgment determining whether Actavis infringed or whether the asserted claims were valid. The public docket reflects resolution through settlement and dismissal rather than a final trial decision. The case therefore created no adjudicated patent barrier against Actavis, although the settlement affected the timing and conditions of potential generic entry.

What was the Indivior v. Actavis case about?

Indivior’s complaint challenged Actavis’s ANDA for generic buprenorphine hydrochloride and naloxone hydrochloride sublingual film. The reference product was Suboxone sublingual film, marketed by Indivior for opioid-use-disorder treatment.

Case profile

Item	Detail
Case	Indivior Inc. v. Actavis Laboratories UT, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:18-cv-00499
Filed	April 9, 2018
Plaintiff	Indivior Inc.
Defendant	Actavis Laboratories UT, Inc., an Actavis/Teva generic subsidiary
Product	Generic buprenorphine hydrochloride and naloxone hydrochloride sublingual film
Reference product	Suboxone sublingual film
Regulatory pathway	ANDA under the Hatch-Waxman Act
Main patents	U.S. Patent Nos. 8,603,514 and 9,931,305
Procedural outcome	Settled and dismissed; no reported merits judgment

The case was part of a broader series of Suboxone patent disputes involving Indivior, Teva, Dr. Reddy’s Laboratories, Mylan and other generic applicants.

What patents did Indivior assert against Actavis?

Indivior asserted patents directed to the composition and structure of its buprenorphine/naloxone film product. The patents were important because they covered more than the active pharmaceutical ingredients. They addressed the delivery platform, polymer matrix, dosage uniformity and characteristics of the finished film.

U.S. Patent No. 8,603,514

U.S. Patent No. 8,603,514, titled “Drug Delivery Composition,” covered aspects of a drug-delivery film containing active ingredients in a polymeric matrix. The patent was associated with Indivior’s sublingual film technology and had been central to other Suboxone ANDA litigation.

The asserted subject matter included film compositions with buprenorphine and naloxone, polymer components and physical or compositional relationships intended to produce a consistent dosage form. The patent’s value came from its relationship to the commercial film rather than from protection of buprenorphine or naloxone as chemical entities.

U.S. Patent No. 9,931,305

U.S. Patent No. 9,931,305 was another “Drug Delivery Composition” patent directed to Indivior’s film technology. It was issued on April 3, 2018, shortly before Indivior filed the Actavis complaint.

The patent claimed film compositions and related dosage-form characteristics. Indivior relied on the patent to challenge Actavis’s proposed generic product through the ANDA litigation process.

Patent-term context

The asserted patents were not composition-of-matter patents covering buprenorphine or naloxone themselves. Their commercial effect depended on whether the patents were listed in the FDA Orange Book, whether the Actavis ANDA included a Paragraph IV certification, and whether the asserted claims survived validity challenges.

The patents had expiration dates in the late-2020s based on their priority dates and applicable patent-term adjustments. The exact blocking effect depended on the claims asserted, Orange Book listings and any settlement-based entry date.

How did the Hatch-Waxman process trigger the lawsuit?

Actavis’s ANDA filing included a Paragraph IV certification challenging Indivior’s listed patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

Indivior filed suit within the statutory 45-day period after receiving Actavis’s notice. The filing triggered an automatic 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and any later court order or settlement.

The litigation therefore served two functions:

1. It allowed Indivior to assert patent rights before generic approval.
2. It delayed final FDA approval while the dispute remained pending.

The case was not a dispute over whether buprenorphine/naloxone could be used to treat opioid-use disorder. It concerned whether Actavis’s proposed film would infringe Indivior’s listed patents and whether those patents were enforceable and valid.

What were the principal legal issues?

Infringement

The infringement analysis would have focused on the composition and structural limitations of the asserted claims. Key issues included:

• Whether Actavis’s proposed film contained the claimed active ingredients in the claimed arrangement.
• Whether the generic film used the claimed polymeric matrix.
• Whether the film satisfied limitations concerning dosage uniformity, thickness, composition or dissolution.
• Whether any differences between the Actavis product and Suboxone avoided literal infringement.
• Whether the doctrine of equivalents could extend the claims to the proposed generic product.

In an ANDA case, infringement is generally assessed from the ANDA specifications, manufacturing process and proposed labeling rather than from commercial sales of the generic product.

Written description and enablement

Indivior’s film patents faced significant written-description risk. In related Suboxone litigation, federal courts held that broad claims to film compositions were not adequately supported by the patent specification. The Federal Circuit has treated the written-description requirement as particularly important where claims cover broad ranges of composition or film characteristics that were not adequately disclosed in the original application.

A written-description challenge could invalidate claims even if Actavis’s product fell within the literal claim language. The central question would be whether the original disclosure demonstrated possession of the full scope of the claimed film composition at the relevant filing date.

Enablement was a related issue. Actavis could argue that the specification did not teach a skilled person how to make and use the full breadth of the claimed compositions without undue experimentation.

Obviousness

Actavis also had a potential obviousness defense based on prior art involving:

• Buprenorphine and naloxone combinations.
• Sublingual dosage forms.
• Polymer-based oral films.
• Taste masking and controlled dissolution.
• Film manufacturing and drug-content uniformity.

Indivior’s response would have emphasized the specific formulation, manufacturing constraints and performance characteristics of the commercial film. Secondary considerations, including commercial success and industry adoption, could support validity but would not overcome a strong showing that the claimed combination was predictable from the prior art.

Prosecution history and enforceability

Actavis could also examine whether Indivior made inaccurate or incomplete representations to the U.S. Patent and Trademark Office. Any inequitable-conduct defense would have required clear and convincing evidence of materiality and specific intent to deceive.

No reported decision in this case established that the asserted patents were unenforceable for inequitable conduct.

What was the litigation outcome?

The case was resolved by settlement and dismissed. There was no reported district court opinion entering judgment after a bench trial, and no reported Federal Circuit decision arising from this specific Actavis docket establishing infringement or invalidity.

The settlement terms were not publicly disclosed in the case record in a manner that provides a complete commercial picture. As a result, the public record does not establish:

• The exact authorized-entry date for Actavis.
• Whether Actavis received an authorized-generic right.
• Whether Actavis agreed to pay or receive consideration.
• Whether Indivior imposed supply, launch or distribution conditions.
• Whether the settlement included restrictions on competing formulations.
• Whether the settlement resolved all claims involving related patents or only the patents in the complaint.

The key legal consequence was that the parties avoided a merits ruling. That outcome preserved flexibility for both sides but left the strength of the asserted claims unresolved in the Actavis case.

How did related Suboxone litigation affect the Actavis case?

The Actavis case was exposed to adverse precedent from other Suboxone patent disputes. In particular, Indivior’s litigation against Dr. Reddy’s and Teva produced decisions addressing the written-description sufficiency of Indivior’s film patents.

In Indivior Inc. v. Dr. Reddy’s Laboratories S.A., the Federal Circuit affirmed invalidity findings against claims of U.S. Patent No. 8,603,514 for lack of written description. The court concluded that the specification did not adequately support the full breadth of the claimed film composition. That decision weakened Indivior’s ability to rely on broad claim language covering commercial buprenorphine/naloxone films.

The precedent did not automatically dispose of every later case. Patent claims, accused products, prosecution histories and procedural records differ. It did, however, increase the litigation risk associated with broad Suboxone film claims and made a negotiated resolution more commercially rational.

What was the Orange Book status of the asserted patents?

Indivior’s enforcement strategy depended on listing the relevant patents in the FDA Orange Book for Suboxone sublingual film. An Orange Book listing gives the patent holder a statutory mechanism to respond to an ANDA Paragraph IV certification.

Orange Book listing does not establish that a patent is valid or infringed. It creates the procedural basis for patent litigation and, in many cases, the 30-month stay of approval.

The relevant issues were:

Orange Book issue	Litigation significance
Patent listing	Allowed Indivior to receive a Paragraph IV notice and sue
Paragraph IV certification	Actavis asserted that the listed patents were invalid, unenforceable or not infringed
30-month stay	Delayed FDA approval while the case proceeded, subject to statutory exceptions
Patent expiration	Defined the maximum ordinary blocking period absent settlement or court action
Claim scope	Determined whether the generic film could enter without infringing

The case did not result in a public judicial ruling removing the patents from the Orange Book.

What was the FDA regulatory status of Actavis’s generic?

Actavis pursued FDA approval through an ANDA rather than through a new drug application or biologics pathway. The proposed product was a generic small-molecule drug-device dosage form, not a biosimilar.

The regulatory dispute was therefore governed by the ANDA framework. Relevant regulatory barriers included:

• Satisfactory FDA review of the ANDA.
• Certification regarding Indivior’s listed patents.
• The 30-month statutory stay.
• Any regulatory exclusivity held by another generic applicant.
• The settlement’s contractual launch restrictions, if any.

Biosimilar risk was not material to this case. Buprenorphine and naloxone are small-molecule active ingredients, and Actavis’s product was subject to generic-drug rules rather than the Biologics Price Competition and Innovation Act.

How strong was Indivior’s patent estate?

Indivior’s estate had meaningful commercial value but material litigation weaknesses.

Strengths

• The patents covered the commercially important film dosage form.
• The patents were listed for the branded Suboxone product.
• The claims could delay ANDA approval through the Hatch-Waxman process.
• The film platform had regulatory and manufacturing complexity that could raise non-patent barriers to entry.
• Indivior had multiple related patents and continuation applications.

Weaknesses

• Broad film claims faced written-description challenges.
• Related Federal Circuit decisions reduced confidence in the enforceability of certain claims.
• The patents did not control the underlying active ingredients.
• Generic applicants could design around specific polymer, composition or physical-property limitations.
• Settlement avoided a definitive ruling confirming a long-term exclusionary right.

The estate was stronger as a portfolio and regulatory-delay tool than as a consistently validated barrier to all generic film competition.

What generic-entry risks did the settlement leave?

The settlement created several possible entry scenarios:

1. Actavis could enter on a negotiated date before the latest asserted patent expiration.
2. Actavis could enter after an agreed date tied to another generic launch or court ruling.
3. Actavis could launch under a license or authorized-generic arrangement.
4. Actavis could remain delayed by FDA, manufacturing or commercial issues even after patent settlement.
5. Other generic applicants could enter independently through separate litigation or settlement agreements.

The settlement did not eliminate competitive risk for Indivior. It transferred the risk from a binary court judgment to the commercial terms of generic entry and the conduct of other ANDA applicants.

How did Actavis compare with other Suboxone generic challengers?

Actavis was one of several generic companies pursuing Suboxone film opportunities. Dr. Reddy’s, Teva and Mylan were involved in related disputes or market-entry activity.

Company	General position in Suboxone competition
Actavis/Teva	Pursued an ANDA for generic buprenorphine/naloxone film and resolved the Delaware litigation by settlement
Dr. Reddy’s	Litigated Indivior film patents and obtained significant favorable validity rulings
Teva	Challenged Indivior patents and participated in broader generic competition
Mylan	Pursued generic buprenorphine/naloxone opportunities and related patent strategies
Indivior	Branded product sponsor and patent holder for Suboxone film

The competitive landscape depended on more than patent expiration. Manufacturing capacity, FDA approval timing, distribution agreements, state opioid-treatment demand and reimbursement contracts also influenced market entry.

What was the commercial exposure for Indivior?

Suboxone film was a core Indivior product. Generic competition threatened:

• Net sales from the branded film.
• Prescription volume.
• Payer formulary position.
• Average selling price.
• Market share in opioid-use-disorder treatment.
• Cash flow available for pipeline development and debt service.

A settlement with one generic applicant could reduce litigation cost and provide launch predictability, but it could also accelerate price erosion if multiple generic products entered around the same time.

Key Takeaways

• Indivior sued Actavis in Delaware in 2018 over an ANDA for generic Suboxone sublingual film.
• The principal asserted patents were U.S. Patent Nos. 8,603,514 and 9,931,305.
• The case involved Paragraph IV certifications and the Hatch-Waxman 30-month stay.
• The litigation ended through settlement and dismissal rather than a reported merits judgment.
• Related Federal Circuit decisions found serious written-description problems in parts of Indivior’s Suboxone film patent estate.
• The asserted patents covered film formulations and delivery technology, not buprenorphine or naloxone as active ingredients.
• Actavis’s settlement preserved the possibility of negotiated generic entry but did not publicly disclose the precise launch terms.
• The case reduced near-term litigation uncertainty while leaving Indivior exposed to broader generic competition.

FAQs

Did Actavis win the Indivior Suboxone patent case?

No reported merits judgment awarded victory to either side. The case was resolved by settlement and dismissal.

What drug was Actavis seeking to market?

Actavis sought approval for generic buprenorphine hydrochloride and naloxone hydrochloride sublingual film, equivalent to Suboxone sublingual film.

Were the Indivior patents composition-of-matter patents?

No. The asserted patents primarily covered film dosage-form and drug-delivery technology rather than the underlying active ingredients.

Did the Actavis case invalidate U.S. Patent No. 9,931,305?

No reported decision in this docket invalidated the patent. The case ended without a merits ruling.

Was Actavis’s product a biosimilar?

No. Buprenorphine/naloxone film is a small-molecule generic product regulated through the ANDA pathway, not a biosimilar under the BPCIA.

References

1. U.S. District Court for the District of Delaware. (2018). Indivior Inc. v. Actavis Laboratories UT, Inc., No. 1:18-cv-00499.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,603,514: Drug delivery composition.

4. U.S. Patent and Trademark Office. (2018). U.S. Patent No. 9,931,305: Drug delivery composition.

5. United States Court of Appeals for the Federal Circuit. (2019). Indivior Inc. v. Dr. Reddy’s Laboratories S.A., 930 F.3d 1325.

6. United States Code. (2024). 21 U.S.C. § 355(j), abbreviated new drug applications and patent certifications.